

## **II. REMARKS**

### **Preliminary Remarks**

Upon entry of this Amendment, claims 11, 13, and 14 will be pending, of which claim 11 is independent. Claims 1 to 10 were previously canceled; claim 12 is canceled by this Amendment. Claims 11 and 13 are amended. Support for the claim amendments can be found in the specification as originally filed (see, for example, page 7). Therefore, the applicant believes that no new matter is added.

Claim 12 was objected to under 37 C.F.R. §1.75 as being a substantial duplicate of claim 11. Claim 12 is canceled rendering this objection moot and the applicant respectfully requests its withdrawal.

This response is filed within the shortened statutory period for response, no fee due. The applicant respectfully requests reconsideration and allowance of the present application.

### **Patentability Remarks**

#### ***Rejection under 35 U.S.C. §101 –***


Claim 13 was rejected under 35 U.S.C. §101 as being directed to non-statutory subject matter. Claim 13 is amended to a method for the treatment of pathologies associated with stress oxidative and/or endothelial dysfunction comprising administering compounds or salts according to claim 11. The amendments to claim 13 render the rejection moot and the applicant respectfully requests its withdrawal.

#### ***Rejection under 35 U.S.C. §112 –***

Claims 11 to 14 were rejected under 35 U.S.C. §112, second paragraph, as being indefinite. The applicant respectfully traverses in view of the preceding claim amendments and succeeding remarks.

Claim 12 is canceled. Claim 11 is amended to compounds or their salts having the following general formula A-B-C-NO<sub>2</sub>, *inter alia*, wherein R' is linear or branched C<sub>1</sub> to C<sub>20</sub> alkyl. As claimed, anti-inflammatory drugs define drugs having formula R-T<sub>1</sub>-Z or R-T<sub>1</sub>-OZ, *i.e.*, the corresponding precursors of A. The amino acids define the

corresponding precursors of B, having the formula  $-T_B-X_2-T_{B1}-$ , in which the  $T_B$  and  $T_{B1}$  free valencies are saturated with  $-OH$  or  $-H$ , as shown in the following example:



Flurbiprofen (formula IX) corresponds to the formula  $R-T_1-OZ$ , wherein Z is H. The amino acid 4-thiazolidincarboxylic acid (formula PIV) corresponds to the formula  $H-T_B-X_2-T_{B1}-OH$ .

Therefore, the applicant respectfully submits that claims 11, 13, and 14 are not indefinite under 35 U.S.C. §112, and respectfully requests withdrawal of this rejection.


### **III. CONCLUSION**

In view of the amendments and remarks above, the applicant respectfully submits that this application is in condition for allowance and requests favorable action thereon.

In the event this response is not timely filed, the applicant hereby petitions for an appropriate extension of time. The fee for this petition, along with any additional fees required with respect to this response, may be charged to Deposit Account No. 01-2300, referencing Attorney Docket No. 026220-00013.

Respectfully submitted,

ARENT FOX PLLC

  
\_\_\_\_\_  
Gautam Prakash, Ph.D.  
Registration No.: 53,481  
Direct Telephone No.: 202-857-6057

Customer No.: **004372**

1050 Connecticut Avenue, N.W.  
Washington, D.C. 20036-5339

Telephone No.: 202-857-6000  
Facsimile No.: 202-857-6395

/GP